Rep. Jared Moskowitz Sells West Pharmaceutical Services, Inc. (NYSE:WST) Stock

Representative Jared Moskowitz (D-Florida) recently sold shares of West Pharmaceutical Services, Inc. (NYSE:WST). In a filing disclosed on March 06th, the Representative disclosed that they had sold between $1,001 and $15,000 in West Pharmaceutical Services stock on February 13th. The trade occurred in the Representative’s “MORGAN STANLEY ACTIVE ASSETS (6)” account.

Representative Jared Moskowitz also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of AbbVie (NYSE:ABBV) on 1/15/2025.
• Purchased $1,001 – $15,000 in shares of McKesson (NYSE:MCK) on 1/15/2025.
• Sold $1,001 – $15,000 in shares of Canadian National Railway (NYSE:CNI) on 1/15/2025.
• Purchased $1,001 – $15,000 in shares of Stryker (NYSE:SYK) on 1/15/2025.
• Purchased $1,001 – $15,000 in shares of The Goldman Sachs Group (NYSE:GS) on 1/15/2025.
• Sold $1,001 – $15,000 in shares of Merck & Co., Inc. (NYSE:MRK) on 1/15/2025.
• Sold $1,001 – $15,000 in shares of Abbott Laboratories (NYSE:ABT) on 1/15/2025.

West Pharmaceutical Services Price Performance

WST traded down $1.21 on Friday, reaching $231.55. The stock had a trading volume of 892,220 shares, compared to its average volume of 973,264. West Pharmaceutical Services, Inc. has a fifty-two week low of $197.01 and a fifty-two week high of $400.88. The firm has a 50-day moving average of $297.42 and a 200-day moving average of $306.29. The company has a current ratio of 2.79, a quick ratio of 2.23 and a debt-to-equity ratio of 0.08. The company has a market capitalization of $16.74 billion, a price-to-earnings ratio of 34.61, a price-to-earnings-growth ratio of 6.74 and a beta of 1.09.

West Pharmaceutical Services (NYSE:WST) last issued its earnings results on Thursday, February 13th. The medical instruments supplier reported $1.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.75 by $0.07. West Pharmaceutical Services had a return on equity of 18.60% and a net margin of 17.03%. The business had revenue of $748.80 million during the quarter, compared to analysts’ expectations of $739.59 million. As a group, sell-side analysts anticipate that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current year.

West Pharmaceutical Services Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 7th. Shareholders of record on Wednesday, April 30th will be issued a $0.21 dividend. The ex-dividend date of this dividend is Wednesday, April 30th. This represents a $0.84 dividend on an annualized basis and a yield of 0.36%. West Pharmaceutical Services’s payout ratio is presently 12.56%.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. UBS Group upgraded West Pharmaceutical Services from a “neutral” rating to a “buy” rating and upped their price target for the company from $350.00 to $390.00 in a research report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $250.00 price target on the stock in a research report on Friday, February 14th. Wolfe Research assumed coverage on West Pharmaceutical Services in a research report on Friday, December 13th. They issued a “peer perform” rating on the stock. KeyCorp reduced their price target on West Pharmaceutical Services from $470.00 to $325.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. Finally, Bank of America upped their price target on West Pharmaceutical Services from $350.00 to $355.00 and gave the company a “buy” rating in a research report on Friday, December 13th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $344.00.

Institutional Investors Weigh In On West Pharmaceutical Services

Several institutional investors and hedge funds have recently made changes to their positions in WST. Asset Management One Co. Ltd. boosted its position in shares of West Pharmaceutical Services by 43.5% during the 3rd quarter. Asset Management One Co. Ltd. now owns 42,048 shares of the medical instruments supplier’s stock valued at $12,621,000 after purchasing an additional 12,745 shares in the last quarter. Impax Asset Management Group plc boosted its position in shares of West Pharmaceutical Services by 56.1% during the 3rd quarter. Impax Asset Management Group plc now owns 3,067 shares of the medical instruments supplier’s stock valued at $921,000 after purchasing an additional 1,102 shares in the last quarter. RTD Financial Advisors Inc. boosted its holdings in West Pharmaceutical Services by 120.2% in the third quarter. RTD Financial Advisors Inc. now owns 1,524 shares of the medical instruments supplier’s stock worth $457,000 after acquiring an additional 832 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in West Pharmaceutical Services by 2.3% in the third quarter. Principal Financial Group Inc. now owns 91,756 shares of the medical instruments supplier’s stock worth $27,541,000 after acquiring an additional 2,037 shares in the last quarter. Finally, Kornitzer Capital Management Inc. KS boosted its holdings in West Pharmaceutical Services by 1.6% in the third quarter. Kornitzer Capital Management Inc. KS now owns 21,334 shares of the medical instruments supplier’s stock worth $6,404,000 after acquiring an additional 334 shares in the last quarter. Institutional investors own 93.90% of the company’s stock.

About Representative Moskowitz

Jared Evan Moskowitz (Democratic Party) is a member of the U.S. House, representing Florida’s 23rd Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Moskowitz (Democratic Party) is running for re-election to the U.S. House to represent Florida’s 23rd Congressional District. He declared candidacy for the 2026 election.

Jared Evan Moskowitz was born in Coral Springs, Florida. Moskowitz graduated from Marjory Stoneman Douglas High School. He earned a bachelor’s degree in political science and government from George Washington University in 2003 and a law degree from Nova Southeastern University in 2007. Moskowitz’s career experience includes working as the director of the Florida Division of Emergency Management and general counsel with AshBritt Inc.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.